Topics

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

19:00 EST 15 Jan 2020 | AAAS

(Institute for Quality and Efficiency in Health Care) Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient for derivation of an added benefitThe small studies on the histology-independent use of the inhibitor have no controls. The amount of other data is also still too small to assess an added benefit.

Original Article: Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

NEXT ARTICLE

More From BioPortfolio on "Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient"

Quick Search

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...